Terizidone | CAS#25683-71-0

MedKoo Cat#: 328068 | Name: Terizidone

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Terizidone is a drug used in the treatment of tuberculosis. Terizidone is used mainly used in multi-drug-resistant tuberculosis (MDR-TB) in conjunction with other second-line drugs. It is a derivate of cycloserine and it is bacteriostatic.

Chemical Structure

Terizidone

CAS#25683-71-0

Theoretical Analysis

MedKoo Cat#: 328068

Name: Terizidone

CAS#: 25683-71-0

Chemical Formula: C14H14N4O4

Exact Mass: 302.1015

Molecular Weight: 302.29

Elemental Analysis: C, 55.63; H, 4.67; N, 18.53; O, 21.17

Price and Availability

Size	Price	Availability	Quantity
100mg	USD 450.00
200mg	USD 650.00
500mg	USD 950.00
1g	USD 1,450.00
2g	USD 2,150.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Terizidone

IUPAC/Chemical Name

4,4'-(((1E,1'E)-1,4-phenylenebis(methanylylidene))bis(azanylylidene))bis(isoxazolidin-3-one)

InChi Key

ODKYYBOHSVLGNU-IAGONARPSA-N

InChi Code

InChI=1S/C14H14N4O4/c19-13-11(7-21-17-13)15-5-9-1-2-10(4-3-9)6-16-12-8-22-18-14(12)20/h1-6,11-12H,7-8H2,(H,17,19)(H,18,20)/b15-5+,16-6+

SMILES Code

O=C1NOCC1/N=C/C2=CC=C(/C=N/C3C(NOC3)=O)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 302.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Walter K, Te Brake LHM, Lemm AK, Hoelscher M, Svensson EM, Hölscher C, Heinrich N. Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures. J Antimicrob Chemother. 2024 Oct 1;79(10):2607-2610. doi: 10.1093/jac/dkae266. PMID: 39110473; PMCID: PMC11441997. 2: Kengo A, Nabeemeeah F, Denti P, Sabet R, Okyere-Manu G, Abraham P, Weisner L, Mosala MH, Tshabalala S, Scholefield J, Resendiz-Galvan JE, Martinson NA, Variava E. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis. Antimicrob Agents Chemother. 2024 May 2;68(5):e0158323. doi: 10.1128/aac.01583-23. Epub 2024 Apr 10. PMID: 38597667; PMCID: PMC11064479. 3: Hughes J. Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review. Pathogens. 2023 Nov 24;12(12):1385. doi: 10.3390/pathogens12121385. PMID: 38133270; PMCID: PMC10745846. 4: Köhler N, Karaköse H, Grobbel HP, Hillemann D, Andres S, König C, Kalsdorf B, Brehm TT, Böttcher L, Friesen I, Hoffmann H, Strelec D, Schaub D, Peloquin CA, Schmiedel S, Decosterd LA, Choong E, Wicha SG, Aarnoutse RE, Lange C, Sánchez Carballo PM. A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis. Pharmaceutics. 2023 Oct 27;15(11):2543. doi: 10.3390/pharmaceutics15112543. PMID: 38004523; PMCID: PMC10674734. 5: van der Laan LE, Garcia-Prats AJ, McIlleron H, Abdelwahab MT, Winckler JL, Draper HR, Wiesner L, Schaaf HS, Hesseling AC, Denti P. Optimizing dosing of the cycloserine pro-drug terizidone in children with rifampicin-resistant tuberculosis. Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0061123. doi: 10.1128/aac.00611-23. Epub 2023 Nov 16. PMID: 37971239; PMCID: PMC10720412. 6: Algharably EA, Kreutz R, Gundert-Remy U. Infant Exposure to Antituberculosis Drugs via Breast Milk and Assessment of Potential Adverse Effects in Breastfed Infants: Critical Review of Data. Pharmaceutics. 2023 Apr 13;15(4):1228. doi: 10.3390/pharmaceutics15041228. PMID: 37111713; PMCID: PMC10143885. 7: Pietersen E, Anderson K, Cox H, Dheda K, Bian A, Shepherd BE, Sterling TR, Warren RM, van der Heijden YF. Variation in missed doses and reasons for discontinuation of anti-tuberculosis drugs during hospital treatment for drug- resistant tuberculosis in South Africa. PLoS One. 2023 Feb 13;18(2):e0281097. doi: 10.1371/journal.pone.0281097. PMID: 36780443; PMCID: PMC9925007. 8: Gausi K, Chirehwa M, Ignatius EH, Court R, Sun X, Moran L, Hafner R, Wiesner L, Rosenkranz SL, de Jager V, de Vries N, Harding J, Gumbo T, Swindells S, Diacon A, Dooley KE, McIlleron H, Denti P. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 2022 Aug 25;77(9):2489-2499. doi: 10.1093/jac/dkac188. PMID: 35678468; PMCID: PMC10146925. 9: Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, Padanilam X, Reuter A, Romero R, Ismail F, Enwerem M, Ferreira H, Conradie F, Naidoo K, Menzies D. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis. 2022 Jul;22(7):1042-1051. doi: 10.1016/S1473-3099(21)00811-2. Epub 2022 May 2. PMID: 35512718; PMCID: PMC9217754. 10: Tomar LR, Pandita N, Arya S, Agrawal CS. Linezolid-Associated Posterior Reversible Leuco-encephalopathy Syndrome in a Patient with Disseminated Tuberculosis. Trop Doct. 2022 Jan;52(1):196-198. doi: 10.1177/00494755211053194. Epub 2021 Dec 6. PMID: 34866511. 11: van der Laan LE, Garcia-Prats AJ, Schaaf HS, Winckler JL, Draper H, Norman J, Wiesner L, McIlleron H, Denti P, Hesseling AC. Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. Front Pharmacol. 2021 Oct 8;12:722204. doi: 10.3389/fphar.2021.722204. PMID: 34690765; PMCID: PMC8531271. 12: Rodionova OY, Titova AV, Demkin NA, Balyklova KS, Pomerantsev AL. Influence of the quality of capsule shell on the non-invasive monitoring of medicines using Terizidone as an example. J Pharm Biomed Anal. 2021 Sep 10;204:114245. doi: 10.1016/j.jpba.2021.114245. Epub 2021 Jul 6. PMID: 34256326. 13: Sonnenkalb L, Strohe G, Dreyer V, Andres S, Hillemann D, Maurer FP, Niemann S, Merker M. Microevolution of Mycobacterium tuberculosis Subpopulations and Heteroresistance in a Patient Receiving 27 Years of Tuberculosis Treatment in Germany. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0252020. doi: 10.1128/AAC.02520-20. Epub 2021 Jun 17. PMID: 33903103; PMCID: PMC8218629. 14: Court R, Centner CM, Chirehwa M, Wiesner L, Denti P, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. Int J Infect Dis. 2021 Apr;105:688-694. doi: 10.1016/j.ijid.2021.03.001. Epub 2021 Mar 5. PMID: 33684562; PMCID: PMC8126338. 15: van der Walt ML, Shean K, Becker P, Keddy KH, Lancaster J. Treatment Outcomes and Adverse Drug Effects of Ethambutol, Cycloserine, and Terizidone for the Treatment of Multidrug-Resistant Tuberculosis in South Africa. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e00744-20. doi: 10.1128/AAC.00744-20. PMID: 33046491; PMCID: PMC7927816. 16: Chirehwa MT, Court R, de Kock M, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, Warren R, Denti P, McIlleron H. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug- Resistant Tuberculosis Patients Dosed with Terizidone. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01381-20. doi: 10.1128/AAC.01381-20. PMID: 32816738; PMCID: PMC7577169. 17: Court R, Chirehwa MT, Wiesner L, de Vries N, Harding J, Gumbo T, Maartens G, McIlleron H. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019 Oct 1;23(10):1068-1074. doi: 10.5588/ijtld.18.0775. PMID: 31627771; PMCID: PMC7402384. 18: Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Cadiñanos Loidi J, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Escobar Salinas N, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Gomez Rosso R, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Martínez Robles E, Matteelli A, Mazza-Stalder J, Moschos C, Muñoz- Torrico M, Mustafa Hamdan H, Nakčerienė B, Nicod L, Nieto Marcos M, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB. Surveillance of adverse events in the treatment of drug- resistant tuberculosis: first global report. Eur Respir J. 2019 Dec 19;54(6):1901522. doi: 10.1183/13993003.01522-2019. PMID: 31601711. 19: Mulubwa M, Mugabo P. Amount of Cycloserine Emanating from Terizidone Metabolism and Relationship with Hepatic Function in Patients with Drug- Resistant Tuberculosis. Drugs R D. 2019 Sep;19(3):289-296. doi: 10.1007/s40268-019-00281-4. PMID: 31396892; PMCID: PMC6738357. 20: Pinheiro PYM, Setúbal S, Oliveira SA. Post-surgical atypical mycobacteriosis in 125 patients in Rio de Janeiro. Rev Soc Bras Med Trop. 2019 Jul 18;52:e20190039. doi: 10.1590/0037-8682-0039-2019. PMID: 31340363.